Light therapy for Parkinson’s: update on medical trials by Dr. Wayne Markman, CEO of Symbyx

In a recent interview, Dr. Wayne Markman, the CEO of Symbyx, provided an update on the company's research into light therapy for Parkinson's disease. Dr. Markman discussed several clinical trials that have been completed or are underway. The initial trials were small, with 12 or fewer participants, but showed promising results. One 12-week trial found statistically significant improvements in both motor and non-motor symptoms. Even more notably, 6 out of the original 12 participants continued the therapy for 5 years and maintained those benefits long-term. A larger 2023 trial involved 60 people. In this study, 68% of those receiving the active light therapy device had clinically meaningful improvements in areas like limb coordination, tremor, gait, and facial expression, compared to a placebo group. Looking ahead, Dr. Markman shared details on two new, more expansive trials getting underway soon. The first is a 60-person randomized, placebo-controlled study in Canada that will assess changes in motor/non-motor symptoms and gut health. The results from this trial will be presented in the coming days. The second upcoming trial will be an even larger study, involving 80-100 participants, at Newcastle University in the UK. This research will take a deeper dive into how light therapy impacts the gut-brain connection in Parkinson's. Researchers will analyze changes in the gut microbiome, inflammation, and the absorption of Parkinson's medications like levodopa. Symbyx has partnered with researchers at universities like Leeds to not only test the clinical efficacy of light therapy but also to uncover the underlying mechanisms of how it may be beneficial for Parkinson's patients. By studying areas like gut health and inflammation, the goal is to better understand why light therapy could have neuroprotective effects and potentially slow disease progression, rather than just temporarily manage symptoms. While more large-scale research is still needed, the early results from Symbyx's studies are promising. The upcoming trial results will be watched closely by the Parkinson's community, as they could pave the way for light therapy to become a valuable complementary approach in managing this complex neurodegenerative disease.